Compare iShares Global Clean Energy ETF (ICLN) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Organon & Co. Common Stock — how do they compare? iShares Global Clean Energy ETF trades at $16.43 (market cap $2.21B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 88 Days and Organon & Co. Common Stock for 0 Days on average.
| ICLN | OGN | |
|---|---|---|
Market Cap | $2.21B | $3.62B |
Volume | 6,641,356 | 2,892,999 |
52-Week High | $23.75 | $13.81 |
52-Week Low | $16.00 | $5.70 |
Typical Hold Time | 88 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN is trading at $16.64, down 2.8% today amid bearish technical signals with 15 sell indicators versus 1 buy. The ETF faces headwinds from clean energy sector volatility, having experienced a 57.2% maximum drawdown historically. Recent news highlights competition from traditional energy ETFs delivering stronger returns with lower fees, though geopolitical tensions are accelerating global renewable energy adoption.
The outlook remains cautious due to high volatility and expense ratio disadvantages versus fossil fuel alternatives. Key risks include sector competition and regulatory uncertainty, while potential catalysts include increased global renewable investment and data center energy demand growth.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
